The double-blind, randomized, placebo-controlled STRIDE trial, which enrolled 792 adults with type 2 diabetes and symptomatic PAD, achieved its primary endpoint, with semaglutide 1 mg ...

Ozempic® (once-weekly semaglutide 1.0 mg) shown to improve walking distance and quality of life in adults with type 2 diabetes and peripheral artery disease (PAD) at ACC 2025 Novo Nordisk A/S Sat ...

Semaglutide 1 mg demonstrated statistically significant and superior improvement in maximum walking distance by 13% over placebo in adults with type 2 diabetes and symptomatic PAD 1. Based on ...

Bagsværd, Denmark, 29 March 2025 – Novo Nordisk today presented the full results from STRIDE, a phase 3b peripheral artery disease (PAD) outcomes trial investigating the effects of once-weekly ...